GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioNxt Solutions Inc (XCNQ:BNXT) » Definitions » Cash And Cash Equivalents

BioNxt Solutions (XCNQ:BNXT) Cash And Cash Equivalents : C$0.08 Mil (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is BioNxt Solutions Cash And Cash Equivalents?

BioNxt Solutions's quarterly cash and cash equivalents declined from Sep. 2023 (C$0.60 Mil) to Dec. 2023 (C$0.36 Mil) but then stayed the same from Dec. 2023 (C$0.36 Mil) to Mar. 2024 (C$0.08 Mil).

BioNxt Solutions's annual cash and cash equivalents declined from Dec. 2021 (C$1.35 Mil) to Dec. 2022 (C$0.14 Mil) but then increased from Dec. 2022 (C$0.14 Mil) to Dec. 2023 (C$0.36 Mil).


BioNxt Solutions Cash And Cash Equivalents Historical Data

The historical data trend for BioNxt Solutions's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioNxt Solutions Cash And Cash Equivalents Chart

BioNxt Solutions Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash And Cash Equivalents
Get a 7-Day Free Trial 0.30 2.59 1.35 0.14 0.36

BioNxt Solutions Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 1.89 0.60 0.36 0.08

BioNxt Solutions Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


BioNxt Solutions  (XCNQ:BNXT) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


BioNxt Solutions Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of BioNxt Solutions's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


BioNxt Solutions (XCNQ:BNXT) Business Description

Traded in Other Exchanges
Address
1820 Fir Street, Suite 270, Vancouver, BC, CAN, V6J 3B1
BioNxt Solutions Inc is a cannabis company engaged in developing analytical testing, processing, and formulation capability in Canada. It is also engaged in research, cultivation, extraction, import, distribution, and manufacturing in Germany. The products of the company include Drug Delivery, Point-of-Care Diagnostics, and Psychedelics.

BioNxt Solutions (XCNQ:BNXT) Headlines

No Headlines